Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl

Episodes 1-4 of 4

• 

  RestartResume

  Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance

  RestartResume

  Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance

  MinuteCE®

  Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance

  1.00 program credit

  • 

    

    Pam R. Taub, MD, FACC, FASPC

  1.00 program credit

• 

  MinuteCE®

  Improving the management of patients with atherosclerotic cardiovascular disease  - The evolving role of icosapent ethyl

  1.00 credit 3 episodes

  • 

    

    Erik Stroes, MD, PhD

  • 

    

    P. Gabriel Steg, MD

  • 

    

    Pam R. Taub, MD, FACC, FASPC

  1.00 credit 3 episodes

• 

  RestartResume

  Challenges in ASCVD reduction and TG-related risk  
  

  RestartResume

  Challenges in ASCVD reduction and TG-related risk  
  

  MinuteCE®

  Challenges in ASCVD reduction and TG-related risk  
  

  1.00 program credit

  • 

    

    Erik Stroes, MD, PhD

  1.00 program credit

• 

  RestartResume

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  RestartResume

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  MinuteCE®

  Perspectives on the results of recent clinical outcomes trials with EPA prevention 
  

  1.00 program credit

  • 

    

    P. Gabriel Steg, MD

  1.00 program credit